Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6951881 | 0.89 | ACE (0.42) | HSP90AA1HSP90AB1ACEKMT2AFABP5 | |
| SCHEMBL13259983 | 0.87 | ACE (0.43) | ACEKMT2AFABP5FABP7DPP8 | |
| SCHEMBL3366520 | 0.85 | ACE (0.54) | ACEKMT2AFABP5FABP7DPP8 | |
| SCHEMBL21899390 | 0.85 | ACE (0.54) | ACEKMT2AFABP5FABP7DPP8 | |
| SCHEMBL30951904 | 0.85 | ACE (0.54) | ACEKMT2AFABP5FABP7DPP8 | |
| SCHEMBL8294724 | 0.84 | KMT2A (0.44) | ACEKMT2AFABP5FABP7DPP8 | |
| SCHEMBL16541854 | 0.77 | AVPR2 (0.42) | KMT2A | |
| SCHEMBL7533300 | 0.74 | DPP8 (0.52) | KMT2AFABP5FABP7DPP8DPP9 | |
| SCHEMBL18939766 | 0.74 | FABP5 (0.41) | ACEKMT2AFABP5FABP7DPP8 | |
| SCHEMBL119605 | 0.74 | ACE (0.52) | ACEFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596732-B2 | Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. | SANOFI-SYNTHELABO (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | AVPR2, AVPR1B, AVPR1A | HSP90AA1 2900/4885HSP90AB1 2658/4885ACE 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.